Published: December 2023
According to a recently published report by Roots Analysis, the growing need to achieve long acting profile of the drugs for weeks, months and years is driving the long acting drugs market growth
The global long acting drugs market is anticipated to grow at a CAGR of 13.1% from 2023-2035, reaching USD 4.62 billion by 2035.
The conventional treatment options available for several diseases are known to be associated with several challenges, such as patient non-compliance, non-adherence to medication and multiple dosing regimen. In order to circumvent the abovementioned challenges, the demand for long-acting drugs is increasing. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot. In addition, these formulations allow specific targeting of the anatomical regions, such as eyes, ears and knees. This leads to reduced systemic exposure and enables the maintenance of high concentration of drug in the area. It is important to highlight that the development and manufacturing of these novel pharmacological modalities require advanced long-acting drug delivery technologies and dedicated expertise available with service providers.
Browse 150+ figures and 170+ market data tables spread across 280+ pages and detailed Table of Content on “Long Acting Drugs Market (Focus on Technology and Service) by Principle, Strategy, Compatible Dosage Form, Type of Molecule used, Type of Material Used and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market.html
Long-acting drug delivery systems are being widely adopted for sustained delivery of pharmaceutical drugs to treat plethora of disease indications, including neurological diseases, infectious diseases, pulmonary diseases, ophthalmological diseases and opioid use disorders. These systems have enabled the effective administration and improved efficacy of peptides, antibodies and vaccines. Moreover, these delivery systems have resulted in prolonged administration of macromolecules for an extended time (weeks, months or years), which are otherwise difficult to administer. The need for novel therapeutics in the market has led to introduction of technological advancements to achieve long-acting profile of the drugs. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. As a result, the market for long acting drug delivery will witness a substantial growth in the foreseen future.
Despite the various advantages of long acting drugs, there are few challenges associated with achieving the desired drug release profile. The timely cessation of the treatment is of paramount importance after the administration of the long-acting drug. For example, in case of a dose administered monthly, the presence of sub-therapeutic concentration of the drug after a month can cause undesired effects in patients. Furthermore, dose dumping is another restraint in this market wherein the drug is rapidly released in the body despite its estimated release timeline. Moreover, in case of long acting implants, the type of material used can pose as a bottleneck wherein removal of the implant from the body is of paramount importance in order to avoid the side-effects (including toxicity).
Given the potential of long acting drug delivery systems to improve patient compliance and adherence to medication, the industry players have undertaken numerous initiatives to enable the clinical and commercial translation of long-acting drugs under development. Moreover, the pharmaceutical industry is extensively focusing on the development of long acting injectables for protein-based drugs and multidrug therapies. The potential of these modalitites is also being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Also, the long acting drugs are also being formulated to support immunotherapies, ocular and joint delivery. Owing to the advanced long acting drug delivery technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome.
The long acting drugs market report also includes detailed profiles of key players (listed below) that offer long acting drug delivery technologies and services pertaining to long acting drug domain:
You Can Download Free Sample PDF Copy of This Report At:
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.firstname.lastname@example.org or email@example.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES